IDEXX Laboratories reports robust fourth-quarter and full-year 2025 results, with double-digit revenue growth fueled by record instrument placements and strategic innovations like InVue DX and CancerDx. The company provides a confident outlook for 2026, targeting continued organic growth despite sector headwinds.
Two French infant formula makers have recalled multiple product batches following the government's decision to slash permissible levels of cereulide, a toxin linked to gastrointestinal illness. The move amplifies a global safety crisis that has seen major brands issue recalls across dozens of countries since late last year.
Canadian junior miner G2 Goldfields Inc. (TSX: GTWO), despite recent losses, is projected by analysts to reach profitability within two years, backed by aggressive growth forecasts and a debt-free balance sheet.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
The energy giant reported industry-leading earnings and cash flow, driven by record production and deep cost cuts, while returning billions to shareholders and outlining an ambitious growth plan through 2030.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
The International Monetary Fund projects average growth in sub-Saharan Africa at 4.6% for the year, edging ahead of Asia's 4.1%, signaling a potential turning point driven by demographics but tempered by significant investment challenges.
After a period of Bitcoin dominance, a confluence of technological maturity, shifting institutional narratives, and regulatory clarity could propel Ethereum back into the spotlight. Analysts point to its foundational role in decentralized finance and a series of upcoming catalysts as reasons for a potential breakout year.
As key financial and digital asset leaders convene in Washington, Coinbase's Head of Global Research expresses strong confidence that the long-stalled CLARITY Act will finally pass this year, citing growing bipartisan support and institutional pressure.
Digital asset investment products witnessed their largest weekly capital flight since late 2025, with Bitcoin and Ethereum bearing the brunt of a $1.73 billion exodus. The sell-off, concentrated in the U.S., underscores a sharp pivot in risk appetite amid shifting macroeconomic winds, though Solana and select regions bucked the trend with modest inflows.
Homebuilder LGI Homes is testing a higher-specification housing model with the launch of its Monte Vista community in Modesto, California. The new single-story homes come with significant included upgrades and integrated solar energy systems, signaling a strategic shift towards energy efficiency and long-term cost-conscious buyers.
Fidelity Investments and Broadcom have settled a legal dispute that threatened Fidelity's access to business-critical software, averting a potential operational crisis. The agreement, reached just before a key court hearing, ensures continued service for a Fidelity subsidiary.
Zions Bancorporation has authorized a new $75 million stock repurchase program, a move analysts see as a bet on its undervalued shares and a commitment to shareholder returns as regional banks navigate a cautious regulatory environment.
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
Google has agreed to a $135 million settlement to resolve a class-action lawsuit alleging unauthorized data collection by its Android operating system, pending court approval. The deal also mandates clearer user controls and disclosures.
Investment firm Curreen Capital posted a 30.97% annual return for 2025, crediting its focus on undervalued, well-managed companies. The firm's latest investor letter highlights home service provider Frontdoor (FTDR) as a key holding, despite it not being among the most popular hedge fund picks.
Investors who held shares in SouthGobi Resources Ltd. (CVE:SGQ) since 2019 have seen a staggering 486% return, a powerful case study in long-term equity investing despite recent volatility.
In a strategic move emphasizing its heritage, Regal Holdings has rebranded its core manufacturing division as the historic West Bend Co., underscoring a commitment to U.S. production and Wisconsin's industrial legacy.
